{"id":"W2889703062","doi":"10.1200/jco.2017.35.15_suppl.6036","title":"A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Adenoid cystic carcinoma; Adverse effect; Cancer; Internal medicine; Sorafenib; Response Evaluation Criteria in Solid Tumors; Progressive disease; Oncology; Gastroenterology; Surgery; Carcinoma; Disease; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001299921,0.001453662,0.001519599,0.0004665091,0.0003783568,0.0007793494,0.0006466619,0.001354734,0.00567423],"category_scores_gemma":[0.0005862354,0.0005073026,0.001020832,0.0003659577,0.0007016186,0.0006392795,0.0003023412,0.002649401,0.001316604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007280875,"about_ca_system_score_gemma":0.001222747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008014193,"about_ca_topic_score_gemma":0.002211701,"domain_scores_codex":[0.9997199,0.0001051319,0.00001214515,0.00006188663,0.00003378915,0.00006701529],"domain_scores_gemma":[0.9995729,0.00005361447,0.00006615082,0.0000356927,0.00003192512,0.00023967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5411898,0.1431299,0.008287478,0.002171732,0.001477721,0.001015357,0.0004449856,0.003207671,0.1450287,0.0005675101,0.01639734,0.1370818],"study_design_scores_gemma":[0.6332043,0.3394885,0.01212122,0.000052641,0.0004392576,0.0007846502,0.00004848772,0.00170184,0.005814028,0.000300303,0.006008971,0.00003589917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9812387,0.003802566,0.0008784679,0.0008791086,0.0002051908,0.006361871,0.00286409,0.0001784876,0.003591521],"genre_scores_gemma":[0.9726005,0.003818814,0.003233991,0.001906218,0.0003266711,0.006100879,0.006232569,0.00006822168,0.005712112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00567423,"threshold_uncertainty_score":0.01898223,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0691088080318681,"score_gpt":0.4482751800529927,"score_spread":0.3791663720211246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}